Drug Type Small molecule drug |
Synonyms Compound 6(Southern Research Institute) |
Target |
Action inhibitors |
Mechanism LRRK2 inhibitors(Leucine-rich repeat serine/threonine-protein kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC18H18N8 |
InChIKeyZQSBNCTWGKRISE-AWEZNQCLSA-N |
CAS Registry2101821-86-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Preclinical | United States | 12 May 2025 |